Toe Pinch Force in Male Type 2 Diabetes Mellitus Patients by Kataoka, Hiroaki et al.
D iabetic polyneuropathy,  a major complication of type 2 diabetes mellitus (T2DM),  develops from 
an early stage of diabetes,  and it causes a variety of dys-
functions.  Muscle weakness of the lower limbs is a 
well-known result of diabetic polyneuropathy.  Lower-
limb muscle strength was reported to be impaired in 
T2DM patients,  and diabetic polyneuropathy was 
shown to be associated with the reduced muscle 
strength [1].  It has been thought that sensory distur-
bance is the main characteristic of diabetic polyneurop-
athy and that symptoms of motor neuropathy,  such as 
muscle weakness,  do not occur until the chronic phase 
[2].  However,  it was clarified that not only sensory dis-
turbance but also motor impairment is observed from 
an early stage of diabetes [1] and that the characteristic 
of the motor impairment is dominant peripheral muscle 
weakness (more severe in the foot than in the lower leg 
and the thigh).  Reduced lower-limb muscle strength 
would make it more difficult to perform aerobic exer-
cise,  and diabetic polyneuropathy commonly affects 
peripheral sensation.  Thus,  the accurate evaluation of 
both lower-limb muscle strength and sensory function 
might be necessary in clinical practice.
Toe pinch force is a parameter of muscle strength 
that is closely associated with stabilization of the pos-
ture [3 , 4],  toe lift-off in the late-stance phase of walk-
ing [5],  and the ability to perform exercise.  We have 
reported on the reproducibility of a new method for the 
measurement of toe pinch force [6],  and we observed 
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We compared the toe pinch force in men with and without type 2 diabetes mellitus (T2DM).  Sixty-eight male 
T2DM patients and 35 apparently healthy men matched for age,  sex,  and body mass index (BMI) were enrolled 
in this cross-sectional study.  We compared the toe pinch force between the subjects with and without T2DM,  
and we evaluated the effect of diabetic polyneuropathy on toe pinch force in the patients.  The toe pinch force of 
the T2DM patients was significantly lower than that of the subjects without diabetes (3.12 ± 1.22 kg vs. 
4.40 ± 1.19 kg,  p< 0.001).  Multiple regression analysis showed that T2DM was a determinant of reduced toe 
pinch force.  In addition,  the toe pinch force of patients with diabetic polyneuropathy was significantly lower 
than that of patients without diabetic polyneuropathy (2.31 ± 0.93 kg vs. 3.70 ± 1.07 kg,  p< 0.001).  Multiple 
regression analysis showed that diabetic polyneuropathy was a determinant of the toe pinch force in men with 
T2DM,  even after adjusting for age,  BMI,  HbA1c,  and duration of diabetes.  Reduced toe pinch force is a fun-
damental feature of motor dysfunction in men with T2DM,  and diabetic polyneuropathy might be associated 
with toe pinch force in these patients.
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that toe pinch force showed a significant positive cor-
relation with other muscle strength parameters in 
T2DM patients such as handgrip strength,  knee exten-
sion force,  and ankle dorsiflexion force [7].  However,  
the correlation was not as strong as we had expected,  
and toe pinch force may thus need to be evaluated in 
addition to other muscle strength parameters in clinical 
practice.  There are no reports of comparisons of toe 
pinch force between subjects with and without T2DM,  
and it has not been known whether toe pinch force is 
reduced in individuals with T2DM compared to healthy 
subjects.
The present cross-sectional study is the first to com-
pare the toe pinch force between subjects with and 
without T2DM.  We also evaluated the relationships 
between toe pinch force and the presence of diabetic 
polyneuropathy and disease factors such as hemoglobin 
A1c (HbA1c),  the duration of diabetes.
Subjects and Methods
T2DM patients and control subjects. Sixty-eight 
men with T2DM and 35 apparently healthy men 
matched for age,  sex,  and body mass index (BMI) were 
enrolled in this cross-sectional study.  The T2DM 
patients were classified as either positive or negative for 
neuropathy according to the criteria for diabetic poly-
neuropathy [8].  Diabetic patients were recruited from 
the inpatients of KKR Takamatsu Hospital (Table 1) 
among 2, 931 outpatients seen at the hospital’s 
Department of Diabetes and Endocrinology from April 
2012 to March 2016 who met the following criteria: (1) 
hospital admission was recommended (346 patients),  
(2) they provided written informed consent to partici-
pate in this study,  (3) they were advised to increase 
their physical activity and perform exercise,  and (4) 
they did not have an existing exercise habit.  Patients 
were excluded if they had severe cardiac or lung disease,  
an acute or chronic musculoskeletal disorder,  acute 
metabolic dysregulation,  other neurological or endo-
crine disorders,  a history of stroke,  previous or current 
asymmetric proximal lower-limb weakness,  toe defor-
mity,  or atrophy of foot muscles,  or if they were already 
performing regular exercise.  Control subjects matched 
for age,  sex,  and BMI were recruited from among the 
KKR Takamatsu Hospital staff.  They had undergone an 
annual heath check-up and had no disorders.
The study was approved by the Ethics Committee of 
KKR Takamatsu Hospital and informed consent was 
obtained from all participants.
Clinical and laboratory measurements. We col-
lected data on the subjects’ age (years),  height (cm),  
body weight (kg),  BMI (kg/m2),  duration of T2DM 
(years),  ankle-brachial index,  cardio-ankle vascular 
index,  medications,  and laboratory test results.  In all 
T2DM patients,  the levels of fasting plasma glucose 
(mg/dl),  HbA1c (%),  total cholesterol (mg/dl),  LDL-
cholesterol (mg/dl),  HDL-cholesterol (mg/dl),  and 
triglycerides (mg/dl) were measured by standard meth-
ods.  The ankle-brachial index and cardio-ankle vascu-
lar index were measured with a VS-1500 (Fukuda 
Denshi,  Tokyo,  Japan).  The diagnosis of T2DM was 
based on the fasting plasma glucose level and HbA1c 
level,  and was made according to the Japan Diabetes 
Society (JDS) guidelines [8].
Measurement of toe pinch force. Toe pinch force 
was measured by using the same dynamometer and 
testing procedure as in previous reports [6 , 7].  The 
dynamometer was a Checker-kun (Nisshin Sangyo,  
Saitama,  Japan).  The subject sat on a chair with arms 
crossed over the chest (90° hip joint flexion,  90° knee 
joint flexion,  and 90° ankle joint flexion),  and the 
dynamometer was attached to the foot at the interdigital 
space between the great toe and second toe.  The test 
was performed twice each on the left and right sides,  
and the best results for the left and right feet were aver-
aged.
Assessment of chronic complications of diabetes.
The diagnoses of diabetic retinopathy and diabetic 
nephropathy were based on the JDS guidelines [8],  
while diabetic polyneuropathy was diagnosed according 
to the Japanese criteria [8].  As in our previous study [7],  
diabetic polyneuropathy was defined as being present if 
the patient had at least 2 of the following: (1) symp-
toms such as dysesthesia,  pain,  and/or loss of sensa-
tion,  (2) decreased or absent Achilles tendon reflex,  
and (3) decreased vibratory sensation (≤ 10 sec).
Statistical analysis. All measured and calculated 
values are expressed as the mean ± standard deviation.  
Comparisons between 2 groups were performed using 
the unpaired-t test,  Mann-Whitney’s U-test and χ2 test.  
Comparisons among 3 groups were done by one-way 
analysis of variance (ANOVA) and the Tukey test.  
P-values < 0.05 were accepted as significant.  We per-
formed a multiple regression analysis to identify factors 
that were determinants of the toe pinch force.
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The required sample size was estimated on the basis 
of findings in our earlier studies [6 , 7],  i.e.,  that the toe 
pinch force of healthy controls and T2DM patients was 
5.8 kg and 3.2 kg,  respectively.  The difference to be 
detected was 2.6 kg,  and the standard deviation was 0.5.  
To detect an effect size of this magnitude with 80% 
power assuming a two-sided test at alpha = 0.05,  it was 
estimated that only 5 participants would be required in 
this study.  The sample size of this study (68 T2DM 
patients and 35 control subjects) was thus considered to 
have sufficient numbers of subjects to evaluate the toe 
pinch force as the main outcome.  In addition,  the 
power of this study was estimated as approx.  1.0 with 
0.05 alpha.
All analyses were performed using JMP 12.1.0 soft-
ware (SAS,  Cary,  NC,  USA).
Results
The clinical profiles of the subjects are summarized 
in Table 1.  There were no significant differences in age,  
height,  body weight,  or BMI between the subjects with 
T2DM (n = 68) and those without T2DM (n = 35).  The 
toe pinch force of the T2DM patients was significantly 
lower than that of the healthy controls (3.12 ± 1.22 kg 
vs. 4.40 ± 1.19 kg,  p < 0.001) (Fig. 1),  by approx.  29%.  
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Table 1　 Clinical characteristics of the patients with type 2 diabetes and control subjects
Control subjects T2DM p-value
n 35 68
Age (years) 58.5±11.5 55.7±12.4 0.258
Height (cm) 167.9±5.7 168.8±5.2 0.468
Weight (kg) 73.1±12.4 77.4±13.1 0.107
BMI (kg/m2) 25.8±3.7 27.0±4.0 0.145
Smoking habit
　Current smoker (n/%) 10/28.6 17/25.0 0.086
　Previous smoker (n/%)  8/22.9 30/44.1
　Non-smoker (n/%) 17/48.5 21/30.9
Drinking habit (n/%) 15/42.9 25/36.8 0.548
HbA1c (%) 9.7±2.5
Fasting plasma glucose (mg/dl) 191.8±100.0
Total cholesterol (mg/dl) 197.8±37.2
LDL-cholesterol (mg/dl) 117.0±25.2
HDL-cholesterol (mg/dl) 46.9±14.8
Triglycerides (mg/dl) 194.0±140.0
Duration of diabetes (years) 9.9±9.1
ABI 1.1±0.1
CAVI 8.4±1.4
Polyneuropathy (n/%) 28/41.4
Nephropathy
　Stage 1 (n/%) 52/76.4
　Stage 2 (n/%)  7/10.3
　Stage 3 (n/%)  8/11.8
　Stage 4 (n/%)  1/1.5
Nephropathy
　Stage 1 (n/%) 42/61.8
　Stage 2 (n/%) 21/30.9
　Stage 3 (n/%)  3/4.4
　Stage 4 (n/%)  2/2.9
Drug theraphy
　Insulin (n/%) 15/22.1
　OHA (n/%) 34/50.0
　Insulin and OHA (n/%) 11/16.2
Value are presented as the mean ±  SD.
T2DM,  type 2 diabetes mellitus; BMI,  body mass index; ABI,  ankle-brachial index; CAVI,  cardio-ankle vascular index; OHA,  oral hypo-
glycemic agent.
We performed the multiple regression analysis using the 
toe pinch force as a dependent variable,  with age,  BMI,  
and T2DM as independent variables.  The results 
showed that only T2DM was a determinant of the toe 
pinch force in all subjects (Table 2).
We next compared the toe pinch force among three 
groups: the controls,  the T2DM patients without dia-
betic polyneuropathy (Non-DPN,  n = 40),  and the 
T2DM patients with diabetic polyneuropathy (DPN,  
n = 28).  The toe pinch force of the DPN group was sig-
nificantly lower than that of the Non-DPN group 
(2.31 ± 0.93 kg vs. 3.70 ± 1.07 kg,  p < 0.001).  Compared 
to the controls,  the toe pinch force in the DPN and 
Non-DPN groups was reduced by approx.  49% and 
16%,  respectively (Fig. 2).  In addition,  the duration of 
T2DM was significantly longer in the DPN group than 
in the Non-DPN group (14.8 ± 9.2 years vs. 6.4 ± 7.2 
years,  p < 0.01) (Table 3).
We evaluated the difference of toe pinch force as 
classified by the sub-criterion of diabetic polyneuropa-
thy (Table 4).  The toe pinch force in patients with an 
abnormal (decreased or absent) Achilles tendon reflex 
was significantly lower than that in the subjects with 
normal Achilles tendon reflex: 2.83 ± 1.19 kg vs. 
3.70 ± 1.09 kg,  p = 0.004,  respectively.  The same was 
true of the subjects with abnormal vibratory sensation 
(2.28 ± 0.79 kg vs. 3.39 ± 1.21 kg,  p = 0.001) and dyses-
thesia,  pain,  and/or loss of sensation symptoms 
(2.00 ± 0.88 kg vs. 3.45 ± 1.11 kg,  p < 0.001).
Lastly,  we performed a multiple regression analysis 
of the 68 patients with T2DM using toe pinch force as 
the dependent variable and age,  BMI,  duration of dia-
betes,  HbA1c,  and diabetic polyneuropathy as inde-
pendent variables.  We found that only diabetic poly-
neuropathy was a determinant of the toe pinch force 
(Table 5).
Discussion
Our main objective in this study was to compare the 
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Table 2　 Multiple regression analysis of the relation between toe pinch force and type 2 diabetes
B β p-value 95% CI
Constant 　3.653 － 　0.008 　0.975 6.331
Age －0.002 －0.015 　0.886 －0.024 0.020
BMI 　0.032 　0.095 　0.353 －0.037 0.102
T2DM －1.314 －0.465 ＜0.001 －1.820 －0.808
R2 ＝0.212.  ANOVA p＜0.001
B,  partial regression coeﬃcient; β,  standardized partial regression ceﬃcient; T2DM,  type 2 diabetes mellitus; BMI,  body mass index.
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Fig. 1　 Comparison of the toe pinch force between the patients 
with T2DM and the control subjects.  T2DM: type 2 diabetes melli-
tus.
＊p＜0.001 vs. control subjects.
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Fig. 2　 Comparison of the toe pinch force among the Non-DPN,  
DPN,  and control subjects.  Non-DPN,  non-diabetic polyneuropa-
thy; DPN,  diabetic polyneuropathy; ＊p＝0.016 vs. control sub-
jects,  ＊＊p＜0.001 vs. control subjects,  †p＜0.001 vs. Non-DPN.
toe pinch force between men with and without T2DM.  
The relationship between the reduction of the toe pinch 
force and T2DM has not been fully established.  
Almurdhi et al.  reported that increased muscle fat mass 
was associated with reduced lower-limb muscle strength 
[9].  There have also been reports that aging is associ-
ated with lower toe muscle strength [3 , 10 , 11].  In the 
present cross-sectional study,  we evaluated the toe 
pinch force in patients with T2DM and compared it 
with that in age-matched controls.  There was also no 
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Table 3　 Clinical characteristics of the non-DPN and DPN groups and the control subjects
Control subjects Non-DPN DPN
n 35 40 28
Age (years) 58.5±11.5 54.6±12.9 57.3±11.8
Height (cm) 167.9±5.7 169.3±5.4 168.0±4.9
Weight (kg) 73.1±12.4 78.7±12.1 75.6±14.4
BMI (kg/m2) 25.8±3.7 27.4±3.9 26.4±4.2
Smoking habit
　Current smoker (n/%) 10/28.6 10/25.0 7/25.0
　Previous smoker (n/%)  8/22.8 17/42.5 13/46.4
　Non-smoker (n/%) 17/48.6 13/32.5 8/28.6
Drinking habit (n/%) 15/42.9 13/32.5 12/42.9
HbA1c (%) 10.1±2.8 9.2±1.9
Fasting plasma glucose (mg/dl) 181.1±104.7 207.2±92.5
Total cholesterol (mg/dl) 202.0±5.9 191.8±7.0
LDL-cholesterol (mg/dl) 120.2±28.9 112.4±18.4
HDL-cholesterol (mg/dl) 44.8±9.9 50.0±19.6
Triglycerides (mg/dl) 178.3±21.8 216.3±2.6
Duration of diabetes (years) 6.4±7.2 14.8±9.2＊
ABI 1.12±0.1 1.09±0.1
CAVI 8.3±1.5 8.6±1.4
Retinopathy
　none (n/%) 32/80.0 20/71.4
　simple (n/%) 3/7.5 4/14.3
　preproliferative (n/%)  4/10.0 4/14.3
　proliferative (n/%) 1/2.5 0/0
Nephropathy
　Stage 1 (n/%) 23/57.5 19/67.9
　Stage 2 (n/%) 13/32.5 8/28.6
　Stage 3 (n/%) 2/5.0 1/3.5
　Stage 4 (n/%) 2/5.0 0/0
Drug theraphy
　Insulin (n/%)  6/15.0 9/32.1
　OHA (n/%) 20/50.0 14/50.0
　Insulin and OHA (n/%)  8/20.0 3/10.7
Value are presented as the mean ± SD.  BMI,  body mass index; ABI,  ankle-brachial index; CAVI,  cardio-ankle vascular index; OHA,  oral 
hypoglycemic agent; ＊p＜0.01 vs. Non-DPN.
Table 4　 Comparison of toe pinch force as classiﬁed by sub-criterion of diabetic polyneuropathy in men with type 2 diabetes mellitus
Achilles tendon relfex Vibratory sensation Symptomsa
Normal Abnormal Normal Abnormal Normal Abnormal
n 23 45 52 16 53 15
Toe pinch force (kg) 3.70±1.09 2.83±1.19＊ 3.39±1.21 2.28±0.79＊ 3.45±1.11 2.00±0.88＊
Values are the mean ± SD.  Symptomsa: adysesthesia,  pain,  and/or loss of sensation.
＊p＜0.01 vs. normal.
age difference between the diabetic patients with and 
without diabetic polyneuropathy,  and thus aging was 
not associated with the lower toe pinch force.
Andersen et al.  reported that the strength of the 
knee flexors,  ankle flexors,  and ankle extensors was 
respectively reduced by 14%,  17%,  and 14% in T2DM 
patients compared with age- and sex-matched controls,  
and they stated that diabetic polyneuropathy was closely 
associated with reduced muscle strength [3].  Our pres-
ent findings showed that the toe pinch force was signifi-
cantly lower in men with T2DM than in men without 
diabetes.  In addition,  the toe pinch force of our 
patients with diabetic polyneuropathy was reduced by 
approx.  49% compared to that of apparently healthy 
men,  and diabetic polyneuropathy was a significant 
determinant of reduced toe pinch force in the T2DM 
patients according to the multiple regression analysis.
There are no prior studies that compared toe pinch 
force in patients with and without T2DM,  to the best of 
our knowledge.  Our present findings provide new evi-
dence about reduced toe pinch force in T2DM.  It is 
estimated that > 50% of T2DM patients have diabetic 
polyneuropathy,  and this polyneuropathy initially 
affects the distal parts of the limbs [12].  The onset of 
diabetic polyneuropathy precedes the development of 
diabetic retinopathy and diabetic nephropathy [13].  
Some patients even have diabetic polyneuropathy before 
developing overt T2DM,  i.e.,  impaired glucose toler-
ance (IGT: 13%) and impaired fasting glucose (IFG:  
11%) [14].  Thus,  the evaluation of the toe pinch force 
could be important since reduced toe pinch force may 
be a fundamental feature of T2DM that should be iden-
tified in clinical practice.
With regard to the relation between foot muscle 
atrophy and T2DM,  there have been some reports that 
intrinsic muscle atrophy was observed in both type 1 
and type 2 DM by magnetic resonance imaging (MRI) 
[15 , 16].  Diabetic polyneuropathy is closely associated 
with intrinsic muscle atrophy [17].  However,  we exclu-
ded T2DM patients with foot muscle atrophy from the 
present study,  and we thus could not evaluate the link 
between intrinsic muscle atrophy and T2DM.  In addi-
tion,  the subjects of Andersen et al.  were patients with 
a mean duration of illness that was ≥ 29 years,  whereas 
it was much shorter (14.8 years) in our study [17].
Ijzerman et al.  reported that muscle weakness of the 
feet was observed before the onset of diabetic polyneu-
ropathy [18].  Andersen et al.  showed that the muscle 
weakness that occurred in type 1 diabetic patients was 
not due to diabetic polyneuropathy or muscle atrophy 
[19].  Muscle weakness might develop earlier than mus-
cle atrophy,  and this link should be investigated in the 
future.
A diabetic patient’s foot can require amputation,  
which markedly reduces the quality of life (QOL);  
preventive foot care is thus quite important for individ-
uals with T2DM.  Various factors are involved in the 
development of a diabetic foot,  such as neuropathy,  
infection,  and ulceration; toe deformity is a cause of 
ulceration.  The characteristic deformity in diabetes is 
hammer/claw toe,  and intrinsic muscle atrophy has 
been suggested to cause this structural change of the 
foot.  Such a deformity combined with a limited range of 
motion of the foot joints [20] and callus formation due 
to elevation of the plantar pressure can lead to ulcer-
ation.  Since diabetic patients have an appreciable risk of 
developing a diabetic foot,  the evaluation of these 
patients’ toe pinch force may provide useful informa-
tion that will help prevent the development or progres-
sion of diabetic foot.
Andersen et al.  reported that patients with T2DM 
had ‘motor dysfunction’ of the lower limbs [13].  
Reduced knee and ankle muscle strength is recognized 
as motor dysfunction,  which is related to future falls,  a 
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Table 5　 Multiple regression analysis of the relation between toe pinch force and diabetic polyneuropathy
B β p-value 95% CI
Constant 　3.376 － 　0.049 　0.009 6.742
Age 　0.008 　0.071 　0.547 　0.071 1.293
BMI 　0.024 　0.071 　0.540 　0.071 1.256
Duration of diabetes －0.024 －0.163 　0.182 －0.163 1.368
HbA1c 　0.066 　0.122 　0.264 　0.122 1.100
DPN －1.212 －0.445 ＜0.001 －1.848 －0.577
R2 ＝0.340.  ANOVA p＜0.001
B,  partial regression coeﬃcient; β, standardized partial regression coeﬃcient; BMI,  body mass index; DPN,  diabetic polyneuropathy.
bedridden state,  and reduced QOL.  Based on our pres-
ent findings,  it is apparent that (1) reduced toe pinch 
force is a characteristic finding in men with T2DM,  and 
(2) impairment of toe pinch force may be an important 
contributor to motor dysfunction.  In clinical practice,  
it may thus be important to prevent motor dysfunction 
in T2DM patients by the performance of resistance 
training of the toes.
This study had some limitations.  First,  it was 
cross-sectional rather than longitudinal,  and we thus 
could not confirm that muscle weakness occurred due 
to diabetic polyneuropathy.  Second,  the definitions of 
diabetic polyneuropathy and muscle atrophy may not 
accurate.  The definition of diabetic polyneuropathy 
used in this study was based on Japanese screening cri-
teria and not on a nerve conduction study.  In addition,  
muscle atrophy of the feet was assessed by an examiner,  
not using MRI.  Third,  we only evaluated men with 
T2DM.  Fourth,  we could not prove the mechanism 
linking reduced toe pinch force with T2DM.  
Nevertheless,  it is noteworthy that reduced toe pinch 
force was a characteristic feature of these patients with 
T2DM,  suggesting that in clinical practice the evalua-
tions of toe pinch force could be useful for prescribing 
exercise and promoting physical activity.  Further stud-
ies are needed to test our present findings.
In conclusion,  we compared the toe pinch force 
between men with and without T2DM,  and the results 
revealed that the toe pinch force in the T2DM patients 
was approx.  29% lower than that of the healthy con-
trols.  Our findings also showed the clinical impact of 
diabetic polyneuropathy on the further reduction of the 
toe pinch force in patients with T2DM.
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